Glenmark Pharmaceuticals shareholding pattern

GLENMARK

1940

0.00 (0.00%)
Last updated on 1 Feb, 2026 | 15:59 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Glenmark Pharmaceuticals Shareholding Pattern

  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

46.65%

Mutual Fund

17.86%

Insurance

1.03%

Foreign Institutional Investors

19.2%

Domestic Institutional Investors

1.24%

Retail

14.02%

Others

0%

Total Promoters
MAR '25
46.65%
JUN '25
46.65%
SEP '25
46.65%
DEC '25
46.65%

Summary

For Year 2025-26, Glenmark Pharmaceuticals reports the following shareholding: Total Promoters at 46.65%, Mutual Fund at 17.86%, Insurance at 1.03%, Foreign Institutional Investors at 19.2%, Domestic Institutional Investors at 1.24%, and Retail at 14.02%. This breakdown provides a quick snapshot of ownership distribution for Glenmark Pharmaceuticals in 2025-26.

Glenmark Pharmaceuticals FAQs

As of 02-2026, the promoter shareholding in Glenmark Pharmaceuticals stands at 46.65% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Glenmark Pharmaceuticals is 19.2% and 1.24% respectively.

The retail shareholding of the Glenmark Pharmaceuticals is 14.02%.

Changes in shareholding patterns of Glenmark Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Glenmark Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.